Filtered By:
Specialty: Lipidology
This page shows you your search results in order of date.
Order by Relevance | Date
Total 122 results found since Jan 2013.
Prevalence, pattern, and correlates of dyslipidemia in Bangladeshi individuals
Stroke and ischaemic heart disease accounted for the top two causes of death in Bangladesh1. Dyslipidemia is identified as a significant independent modifiable risk factor for cardiovascular diseases (CVDs) that has been strongly connected to the pathophysiology of CVDs2. Dyslipidemia is defined as the presence of abnormal blood concentrations of one or more of the following lipids (fat): total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and triglycerides (TG)3.
Source: Journal of Clinical Lipidology - September 16, 2023 Category: Lipidology Authors: Md Tauhidul Islam, Md Taqbir Us Samad Talha, Sabit Saad Shafiq, Tapas Mazumder, Rajat Das Gupta, Shahjahan Siraj Tags: Original Research Source Type: research
Triglyceride glucose-body mass index and cardiovascular mortality in patients undergoing peritoneal dialysis: a retrospective cohort study
Recent studies have shown that triglyceride glucose-body mass index (TyG-BMI) is associated with the risk of ischemic stroke and coronary artery disease. However, little attention has been given to the associa...
Source: Lipids in Health and Disease - September 5, 2023 Category: Lipidology Authors: Cuixia Zhan, Yuan Peng, Hongjian Ye, Xiangwen Diao, Chunyan Yi, Qunying Guo, Wei Chen and Xiao Yang Tags: Research Source Type: research
Admission LDL-cholesterol, statin pretreatment and early outcomes in acute ischemic stroke
Elevated LDL-cholesterol (LDL-C) levels increase the risk of stroke and vascular events. Initiation and maintenance of lipid-lowering therapy after acute ischemic stroke (AIS) appears to be guided by LDL-C levels.1 The EUROASPIRE III stroke-specific module shows that secondary prevention and risk factor control in patients after ischemic stroke need to be improved since about half of patients are not achieving target lipid levels defined in European guidelines.2 However, lower levels of LDL-C are paradoxically associated with increased mortality in ST elevation myocardial infarction patients.
Source: Journal of Clinical Lipidology - August 7, 2023 Category: Lipidology Authors: Joon-Tae Kim, Ji Sung Lee, Beom Joon Kim, Jihoon Kang, Keon-Joo Lee, Jong-Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Jae-Kwan Cha, Dae-Hyun Kim, Tai Hwan Park, Kyungbok Lee, Jun Lee, Keun-Sik Hong, Yong-Jin Cho, Hong-Kyun Park, Byung-Chul Lee, Kyung Tags: Original Research Source Type: research
Primary Prevention of Stroke is Strongly Correlated with Low-Density-Lipoprotein Cholesterol Reduction: A Meta-Regression Analysis
Statins have become the cornerstone of therapy for both primary and secondary prevention of cardiovascular (CV) and cerebrovascular diseases (CVD). Numerous studies and meta-analyses have documented these benefits independent of low-density-lipoprotein cholesterol (LDL-C) lowering. There are discrepant reports regarding the dependence of the stroke benefits on the baseline LDL-C levels. The relevance of LDL-C reduction from baseline in the era of pleiotropic benefits needs further exploration, especially, while comparing the primary stroke cohort with the secondary stroke prevention cohort.
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Samit Ghosal, Krishna G Seshadri Tags: Lipid Management in Special Populations Source Type: research
Improvement in Cognitive Function and Reducing the Risk of Developing Cardiovascular Events/ Stroke in Homocysteinemia
A patient presenting with recurrent stroke and angina was diagnosed with homocysteinemia. Elevated homocysteine levels increase the risk of atherosclerosis and venous thrombosis, which can lead to strokes, and cardiovascular events, while significantly impacting an individual's brain function, including the onset of depression/psychosis.
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Kirollos Gabrah, Mirra Srinivasan, Hadia Arzoun, Siji Thomas, Barry Tedder Tags: Genetic Disorders Source Type: research
Prevalence of Lipoprotein(a) Measurements in Patients with or at Risk of Cardiovascular Disease
Elevated lipoprotein(a) [Lp(a)] is an atherogenic, cholesterol-containing, genetically-determined, independent risk factor for ischemic cardiovascular disease outcomes. In clinical settings, elevated serum Lp(a) predicts increased myocardial infarction, stroke, peripheral arterial disease, and aortic valve stenosis risk. Knowledge of a patient's Lp(a) may modify management, including a lower low-density lipoprotein cholesterol (LDL-C) goal and consideration of using a PCSK9 inhibitor.
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Bhavana Upadhyaya, Robert C. Block, Ying Wang, Jeffrey T. Bruckel Tags: Epidemiology of Cardiovascular Disease Source Type: research
Trends in Lipoprotein(a) Testing at the University of Pennsylvania Health Systems from 2012-2021
Lipoprotein(a) [Lp(a)] is an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Elevated Lp(a) levels are associated with a higher risk for myocardial infarction, coronary artery disease, aortic stenosis, and stroke. Lp(a) levels are primarily genetically driven and minimally impacted by diet and lifestyle, so a single measurement can identify individuals with elevated levels. However, Lp(a) screening has not been widely integrated into clinical practice in the United States.
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Archna Bajaj, Lakshmi Parvathinathan, Marjorie Risman, Ahmad Alsattari, Daniel J. Rader Tags: Best Practices in Lipid Management Source Type: research
Associations of Chinese visceral adiposity index and new-onset stroke in middle-aged and older Chinese adults: an observational study
Stroke represents the second most prevalent contributor to global mortality. The Chinese Visceral Adiposity Index (CVAI) serves as an established metric for assessing visceral adiposity in the Chinese populati...
Source: Lipids in Health and Disease - June 19, 2023 Category: Lipidology Authors: Hongyu Zhang, Qi Zhan, Fayan Dong, Xueting Gao, Fanyue Zeng, Jiahao Yao, Yifan Gan, Shuhuai Zou, Jianheng Gu, Hongqian Fu and Xuefeng Wang Tags: Research Source Type: research
Incident CHD and ischemic stroke associated with lipoprotein(a) by levels of Factor VIII and inflammation
High lipoprotein(a) [Lp(a)] is a risk factor for atherosclerotic cardiovascular disease (ASCVD).1-3 Lp(a) has pro-inflammatory and pro-thrombotic properties, both of which may contribute to an increased ASCVD risk.4-7 Prior studies suggest that high Lp(a) may be associated with an increased risk for ASCVD events in adults with high-sensitivity C-reactive protein (hs-CRP) ≥2 mg/L, a marker of inflammation, but not among those with hs-CRP
Source: Journal of Clinical Lipidology - June 10, 2023 Category: Lipidology Authors: Lisandro D. Colantonio, Sascha N. Goonewardena, Zhixin Wang, Elizabeth A. Jackson, Michael E. Farkouh, Mei Li, Waqas Malick, Shia T. Kent, J. Antonio G. L ópez, Paul Muntner, Vera Bittner, Robert S. Rosenson Tags: Original Research Source Type: research
Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: a systematic review
Atherosclerotic cardiovascular (CV) disease is one of the leading causes of global mortality. It is a progressive inflammatory disease that involves lipid accumulation in the sub-intimal layer of the arterial wall, resulting in gradual plaque formation1. Plaque rupture is implicated in a large proportion of major adverse cardiovascular events (MACE), including acute coronary syndrome and ischemic stroke. The presence of intraplaque neovascularization (IPN) in large arterial plaques have been associated with an increased risk of rupture and plaque vulnerability.
Source: Journal of Clinical Lipidology - April 26, 2023 Category: Lipidology Authors: Edward Cui, Georgia Kersche, Nicholas Grubic, Marie-France H étu, Stephen C. Pang, Henrik Sillesen, Amer M. Johri Tags: Review Article Source Type: research
Determination of endogenous sphingolipid content in stroke rats and HT22 cells subjected to oxygen-glucose deprivation by LC ‒MS/MS
Stroke is the leading cause of death in humans worldwide, and its incidence increases every year. It is well documented that lipids are closely related to stroke. Analyzing the changes in lipid content in the ...
Source: Lipids in Health and Disease - January 25, 2023 Category: Lipidology Authors: Keqi Zeng, Xin Zhou, Wanyi Liu, Cong Nie and Yingfeng Zhang Tags: Research Source Type: research
Relationship between early-onset stroke and triglyceride-glucose index among young Chinese adults
The triglyceride –glucose index (TyG index), an alternative indicator of peripheral insulin resistance (IR), is associated with cardiovascular disease (CVD) in the general population. The aim of this research w...
Source: Lipids in Health and Disease - January 11, 2023 Category: Lipidology Authors: Wenqi Xu, Haiyan Zhao, Xu Han, Jianrong Liu, Haixia Li, Junyan Sun, Aijun Xing, Shuohua Chen, Shouling Wu and Yuntao Wu Tags: Research Source Type: research
Recommended and Observed Statin Use among U.S. Adults – National Health and Nutrition Examination Survey, 2011-2018
Heart disease and stroke are the first and fifth leading causes of death in the United States.1 A leading risk factor for both conditions, high blood cholesterol levels are positively associated with atherosclerotic cardiovascular disease (ASCVD).2-5 The 2013 American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2013 Cholesterol Guideline) eliminated specific LDL-c treatment targets, shifted treatment focus to use of HMG-CoA reductase inhibitors (statins), identified four patient groups most likely to bene...
Source: Journal of Clinical Lipidology - December 24, 2022 Category: Lipidology Authors: Angela M. Thompson-Paul, Cathleen Gillespie, Hilary K. Wall, Fleetwood Loustalot, Laurence Sperling, Yuling Hong Tags: Original Research Source Type: research
Statin therapy for primary prevention in men: What is the role for coronary artery calcium?
Statin therapy is widely prescribed for patients with established ASCVD (secondary prevention). Meta-analysis of randomized clinical trials (RCTs) show conclusively that statins substantially reduce recurrent major ASCVD events (myocardial infarction and stroke)1. More problematic is use of statins for patients without ASCVD (primary prevention). RCTs clearly demonstrate that statins can lower ASCVD for primary prevention in patients at higher risk for future vascular events2-4; however, the number needed to treat (NNT) to prevent one ASCVD event is much higher for primary prevention than for secondary prevention.
Source: Journal of Clinical Lipidology - November 23, 2022 Category: Lipidology Authors: Scott M. Grundy, Jijia Wong, Gloria L. Vega Source Type: research
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease –related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform trea...
Source: Journal of Clinical Lipidology - August 28, 2022 Category: Lipidology Authors: Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, B ørge G. Nordestgaard, Carl E. Orringer Source Type: research
